Close Menu

At the Bio-IT conference this week, Microsoft introduced Amalga Life Sciences, according to Bio-IT World. Amalga is part of Microsoft's "plan create a single information highway and data aggregation/modeling platform that spans basic research, clinical trials, health care delivery, and consumer health information needs." With this Microsoft will be targeting academic medical centers, biotechs, and pharma. Consider yourself warned.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

23andMe has launched a new tool that estimates someone's risk of developing severe COVID-19 if infected, Bloomberg reports.

The Guardian reports that Pasteur Institute researchers are halting their development of a SARS-CoV-2 vaccine following disappointing initial results.

The Wall Street Journal reports that an increased number of younger patients have been hospitalized as the new SARS-CoV-2 strain spread across the UK.

In Cell this week: proteomic patterns among COVID-19 affected tissue samples, transcriptome atlas of developing intestines, and more.